All Stories

  1. OMERACT systemic lupus erythematosus domain survey
  2. Risk of chronic kidney disease in 260 patients with lupus nephritis: analysis of a nationwide multicentre cohort with up to 35 years of follow-up
  3. Combination treatment with rituximab and belimumab in shrinking lung syndrome in systemic lupus erythematosus
  4. SLE‐DAS remission and low disease activity states discriminate drug from placebo and better health‐related quality of life
  5. Anti-SSA Ro52 and anti-Ro60 autoantibodies: association with clinical phenotypes
  6. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
  7. What is the best instrument to measure disease activity in SLE? – SLE-DAS vs Easy BILAG
  8. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study
  9. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist’s judgement?
  10. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up
  11. Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective
  12. Anti-Ku antibody syndrome: is it a distinct clinical entity? A cross-sectional study of 75 patients
  13. Creation and Validation of the European Portuguese Version of the Systemic Lupus Erythematous Quality of Life Questionnaire
  14. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort
  15. Predictors of hospitalization in patients with systemic lupus erythematosus: a 10-year cohort study
  16. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
  17. POS0861 ANTI-Ku ANTIBODY SYNDROME: IS IT A DISTINCT CLINICAL ENTITY? A CLUSTER ANALYSIS OF 75 PATIENTS.
  18. POS0759 DOES LLDAS DEFINITION MATCH THE RHEUMATOLOGIST OPINION? THE FIRST VISIT EVALUATION OF A LONGITUDINAL SPANISH MULTICENTER STUDY TO ASSESS REASONS OF DISAGREEMENT.
  19. POS0119 SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES ARE ASSOCIATED WITH IMPROVED HEALTH-RELATED QUALITY OF LIFE AND FATIGUE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
  20. OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.
  21. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort
  22. Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study
  23. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity
  24. POS0762 CAN THE SLE-DAS SUBSTITUTE BILAG TO MEASURE LUPUS DISEASE ACTIVITY IN CLINICAL TRIALS? POST-HOC ANALYSIS OF THE BLISS-76 TRIAL
  25. OP0293 OPTIMIZING A TOOL TO IDENTIFY LUPUS FLARES IN DAILY CLINICAL PRACTICE: SLE-DAS FLARE VERSUS SELENA FLARE INDEX
  26. POS0713 PREDICTORS OF HOSPITALIZATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 10-YEAR COHORT STUDY OF 398 PATIENTS FROM A TERTIARY CENTRE
  27. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts
  28. Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study
  29. Effectiveness of reproductive health counseling of women with systemic lupus erythematosus: observational cross-sectional study at an academic lupus clinic
  30. FRI0155 Α MULTICENTER “AT-RISK” COHORT FOR THE DISCOVERY OF ENVIRONMENTAL, CLINICAL AND MOLECULAR PREDICTORS FOR THE TRANSITION INTO SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
  31. SAT0184 MAINTENANCE THERAPY WITH AZATHIOPRINE ASSOCIATED WITH HIGHER RISK OF FLARE IN PROLIFERATIVE LUPUS NEPHRITIS
  32. OP0092 OPTIMIZING A DEFINITION OF LUPUS LOW DISEASE ACTIVITY STATE (LDA) FOR DAILY CLINICAL PRACTICE: SLE-DAS LDA VS LLDAS
  33. SAT0185 PREDICTORS OF POOR RENAL OUTCOME IN PATIENTS WITH PROLIFERATIVE LUPUS NEPHRITIS: A 36-MONTHS COHORT STUDY
  34. FRI0165 RISK OF CKD IN MEMBRANOUS AND PROLIFERATIVE LUPUS NEPHRITIS - ANALYSIS OF A NATIONWIDE MULTICENTRE COHORT
  35. I2 How to optimize use of glucocorticoids in SLE
  36. Response to: ‘Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population’ by Rodríguez-González et al
  37. How to investigate: Very early inflammatory rheumatic diseases
  38. Response to: ‘SLE-DAS: ready for routine use’ by Mathew et al
  39. THU0267 THE SLE DISEASE ACTIVITY SCORE (SLE-DAS) ENABLES ACCURATE DEFINITIONS OF SLE REMISSION AND LDA AS ACHIEVABLE TARGETS IN DISEASE MANAGEMENT
  40. Response to: ‘Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort’, by Hassan et al
  41. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36–month prospective cohort study of 334 patients
  42. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus
  43. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity
  44. AB0215 Association of rheumatoid factor immunoglobulin a seropositivity with risk of erosive arthritis in patients with rheumatoid arthritis: an observational study
  45. FRI0641 Detection of changes in sle disease activity is highly improved with sle-das as compared to sledai: derivation and preliminary validation of the sle disease activity score (SLE-DAS)
  46. Asymptomatic Rhabdomyolysis and Digital Necrosis—Clues for a Rheumatic Disease
  47. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis
  48. Risk of damage and mortality in SLE patients fulfilling the ACR or only the SLICC classification criteria. A 10-year, inception cohort study
  49. THU0362 Effect of biotechnological drugs on extra-articular manifestations of ankylosing spondylitis: systematic review
  50. OP0206 Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients
  51. Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre
  52. Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register
  53. The weaker sex: Characterization of gender disparities in a nationwide lupus register (Reuma.pt/SLE)
  54. Performance of SLE Classification Criteria: Are the new SLICC criteria better?
  55. AB0608 Greater Organ Involvement and Disease Activity in Childhood-Onset than Adult-Onset With SLE (DATA from Reuma.Pt/Les): Table 1.
  56. Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets
  57. CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus
  58. Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry
  59. THU0026 Greater Diagnostic Delay in Early-Onset than in Late-Onset Systemic Lupus Erythematosus - Data from Reuma.Pt/Les: Table 1.
  60. THU0011 The SLICC 2012 Classification Criteria Have Higher Sensitivity for SLE than the ACR 1997 Criteria: A Study of 2055 Patients from A Real-Life, Multicenter, International SLE Cohort
  61. FRI0428 The Weaker Sex: Characterization of Gender Disparities in A Nationwide Lupus Registry (REUMA.PT LES): Table 1.
  62. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study
  63. A5.3 Alterations on Peripheral Blood B Cell Compartments in Systemic Lupus Erythematosus: Relevance For Monitoring Lupus Activity and Therapy
  64. NK cells dysfunction in systemic lupus erythematosus: relation to disease activity
  65. Tolerogenic versus Inflammatory Activity of Peripheral Blood Monocytes and Dendritic Cells Subpopulations in Systemic Lupus Erythematosus
  66. PMS30 Cost-Effectiveness of Tocilizumab Compared to Standard Therapeutic Sequences for the Treatment of Moderate/Severe Rheumatoid Arthritis (RA) Patients in Portugal
  67. Th17 cells in systemic lupus erythematosus share functional features with Th17 cells from normal bone marrow and peripheral tissues
  68. The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice
  69. Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus
  70. Epidemiology of Systemic Lupus Erythematosus
  71. Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus
  72. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients
  73. Soft tissue injections
  74. Epidemiology of systemic lupus erythematosus
  75. Differential Male and Female Adrenal Cortical Steroid Hormone and Cortisol Responses to Interleukin‐6 in Humans